ReviewObesity surgery2026
Long-Term Effects of Biliopancreatic Diversion (BPD), Biliopancreatic Diversion with Duodenal Switch (BPD-DS), and Single Anastomosis Duodeno‑Ileal Bypass with Sleeve Gastrectomy (SADI‑S) in Patients with Obesity: A Meta-Analysis.
Review in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe long-term outcomes of biliopancreatic diversion (BPD), BPD with duodenal switch (BPD-DS), and single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) in patients with obesity are not well established.
methodsA systematic search of PubMed, Embase, Scopus, and Web of Science was conducted until October 11, 2025, following PRISMA guidelines. Studies reporting outcomes at ≥ 10 years following the specified procedures were included.
resultsA total of 22 studies with 2156 patients were included. BPD and BPD-DS were associated with a mean BMI reduction of 19.02 kg/m². BPD-DS achieved total weight loss (TWL) of 36.34% and an excess weight loss (EWL) of 75.22%. Resolution rates for diabetes, hypertension, hyperlipidemia, and obstructive sleep apnea were 78%, 63%, 83%, and 89%, respectively. Major long-term complications included revision surgery (3%), anemia (19%), iron deficiency (34%), and bone disorders (25%). Compared with RYGB, BPD and BPD-DS achieved greater BMI reduction (mean difference 6.31 kg/m², 95% CI: 3.16, 9.47) and higher diabetes resolution (OR 3.49, 95% CI: 1.11, 10.91), but with a higher rate of cholecystectomy. Diabetes relapse after BPD and BPD-DS occurred in 15% of patients, with significant reductions in fasting blood sugar and HbA1c. Limited data from two studies on SADI-S showed sustained weight loss (TWL 34.4%, EWL 80.4%) but notable rates of reoperation due to nutritional complications.
conclusionOverall, BPD and BPD-DS provide lasting weight loss and metabolic benefits, but careful patient selection and ongoing multidisciplinary care are important because of the risk of malnutrition. Long-term data on SADI-S appear promising but remain limited.
Indexed as
Identifiers
42836947What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.